Incyte Reaches Agreement with FDA on MF Drug

July 22, 2009

The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis. The Special Protocol Assessment (SPA) for the design of the trial is related to reduction in spleen size, a goal Incyte is confident they will meet.

The trial, which will begin in August, has recruited 240 patients.

Source:

Reuters

Incyte press release